Incyte (INCY) Net Cash Flow Growth (3y) (2013 - 2026)
Incyte (INCY) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 32.17% |
| 10 | Incyte | 23.74 Bn | 19.72 Bn | 1.17 Bn | 68.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.83% |
| Dec 31, 2025 | 35.23% |
| Sep 30, 2025 | 25.31% |
| Jun 30, 2025 | -56.49% |
| Mar 31, 2025 | 8.53% |
| Dec 31, 2024 | 86.81% |
| Sep 30, 2024 | 15.99% |
| Jun 30, 2024 | -173.71% |
| Mar 31, 2024 | -5.75% |
| Dec 31, 2023 | -33.71% |
| Sep 30, 2023 | -17.87% |
| Jun 30, 2023 | 3.36% |
| Mar 31, 2023 | 45.17% |
| Dec 31, 2022 | 25.74% |
| Sep 30, 2022 | -3.87% |
| Jun 30, 2022 | 14.98% |
| Mar 31, 2022 | 13.66% |
| Dec 31, 2021 | 4.02% |
| Sep 30, 2021 | 3.38% |
| Jun 30, 2021 | 55.29% |